Effect of pregnancy

Journal of Acquired Immune Deficiency Syndromes

Volumn 38, Issue SUPPL. 1, 2005, Pages

  Watts, Heather ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD38 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; RNA DIRECTED DNA POLYMERASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA;

CLINICAL TRIAL; CONFERENCE PAPER; DEVELOPING COUNTRY; DISEASE COURSE; DRUG EFFICACY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOSTIMULATION; INFANT; INFECTION RISK; LYMPHOCYTE COUNT; NONHUMAN; POLYMERASE CHAIN REACTION; PREGNANCY; PRIORITY JOURNAL; PUERPERIUM; TH1 CELL; TH2 CELL; VERTICAL TRANSMISSION; VIRUS DETECTION; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 18244410433     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000167041.35311.be     Document Type: Conference Paper

References (20)

1. Burns DN, Landesman S, Minkoff H, et al. The influence of pregnancy on human immunodeficiency virus type 1 infection: antepartum and postpartum changes in human immunodeficiency virus type 1 viral load. Am J Obstet Gynecol. 1998; 178:355-359.
2. Cao Y, Krogstad P, Korber BT, et al. Maternal HIV-1 viral load and vertical transmission of infection: the Ariel Project for the prevention of HIV transmission from mother to infant. Nat Med. 1997; 3:549-552.
3. Watts DH, Lambert J, Stiehm ER, et al., for the PACTG 185 Study Team. Progression of HIV disease among women following delivery. J Acquir Immune Defic Syndr. 2003; 33:585-593.
4. Henin Y, Mandelbrot L, Henrion R, et al. Virus excretion in the cervicovaginal secretions of pregnant and nonpregnant HIV-infected women. J Acquir Immune Defic Syndr. 1993; 6:72-75.
5. Nielsen K, Boyer P, Dillon M, et al. Presence of human immunodeficiency virus (HIV) type 1 and HIV-1-specific antibodies in cervicovaginal secretions of infected mothers and in the gastric aspirates of their infants. J Infect Dis. 1996; 173:1001-1004.
6. Shaheen F, Sison AV, McIntosh L, et al. Analysis of HIV-1 in the cervicovaginal secretions and blood of pregnant and nonpregnant women. J Hum Virol 1999; 2:154-166.
7. John GC, Nduati RW, Mbori-Ngacha D, et al. Genital shedding of human immunodeficiency virus type 1 DNA during pregnancy: association with immunosuppression, abnormal cervical or vaginal discharge, and severe vitamin A deficiency. J Infect Dis. 1997; 175:57-62.
8. Loussert-Ajaka I, Mandelbrot L, Delmas MC, et al. HIV-1 detection in cervicovaginal secretions during pregnancy. AIDS. 1997; 11:1575-1581.
9. Panther LA, Tucker L, Xu C, et al. Genital tract human immunodeficiency virus type 1 (HIV-1) shedding and inflammation and HIV-1 env diversity in prenatal HIV-1 transmission. J Infect Dis. 2000; 181:555-563.
10. John GC, Nduati RW, Mbori-Ngacha DA, et al. Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J Infect Dis. 2001; 183:206-212.
11. Clemetson DB, Moss GB, Willerford DM, et al. Detection of HIV DNA in cervical and vaginal secretions: prevalence and correlates among women in Nairobi, Kenya. JAMA. 1993; 269:2860-2864.
12. Kreiss J, Willerford DM, Hensel M, et al. Association between cervical inflammation and cervical shedding of human immunodeficiency virus DNA. J Infect Dis. 1994; 170:1597-1601.
13. Chuachoowong R, Shaffer N, Siriwasin W, et al. Short-course antenatal zidovudine reduces both cervical human immunodeficiency virus type 1 levels and risk of perinatal transmission. J Infect Dis. 2000; 181:99-106.
14. Tuomala RE, O'Driscoll PT, Bremer JW, et al., for the Women and Infants Transmission Study. Cell-associated genital tract virus and vertical transmission of human immunodeficiency virus type 1 in antiretroviral- experienced women. J Infect Dis. 2003; 187:375-384.
15. Rich KC, Siegel JN, Jennings C, et al. CD4+ lymphocytes in perinatal human immunodeficiency virus (HIV) infection: evidence for pregnancy-induced immune depression in uninfected and HIV-infected women. J Infect Dis. 1995; 172:1221-1227.
16. Mikyas Y, Aziz N, Harawa N, et al. Immunologic activation during pregnancy: serial measurement of lymphocyte phenotype and serum activation molecules in HIV-infected and uninfected women. J Reprod Immunol. 1997; 33:157-170.
17. Rich KC, Siegel JN, Jennings C, et al. CD8+ lymphocytes in pregnancy and HIV infection: characterization of CD8+ subpopulations and CD8+ noncytotoxic antiviral activity. AIDS Res Human Retroviruses. 1999; 15:665-670.
18. Burns DN, Nourjah P, Wright DJ, et al. Changes in immune activation markers during pregnancy and postpartum. J Reprod Immunol. 1999; 42:147-165.
19. Saada M, Le Chenadec J, Berrebi A, et al. Pregnancy and progression to AIDS: results of the French prospective cohorts. AIDS. 2000; 14:2355-2360.
20. Weisser M, Rudin C, Battegay M, et al. Does pregnancy influence the course of HIV infection? Evidence from two large Swiss cohort studies. J Acquir Immune Defic Syndr Hum Retrovirol. 1998; 15:404-410.